エドガーで原本を確認する
FORM 6-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
dated March 6, 2024
Commission File Number 0-51504
GENETIC TECHNOLOGIES LIMITED
(Exact Name as Specified in its Charter)
N/A
(Translation of Registrant’s Name)
60-66 Hanover Street
Fitzroy
Victoria 3065 Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: March 7, 2024
| GENETIC TECHNOLOGIES LIMITED | ||
| By: | /s/ Tony Di Pietro | |
| Name: | Tony Di Pietro | |
| Title: | Company Secretary | |
|
|
EXHIBIT INDEX
| Exhibit | Description of Exhibit | |
| 99.1 |
|
|
Exhibit 99.1
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
| Name of entity: Genetic Technologies Limited |
| ABN: 17 009 212 328 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director | Peter Irwin Rubenstein |
| Date of last notice | 27 December 2023 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or indirect interest | Indirect | |
|
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. |
Irwin Biotech Nominees Pty Ltd <BIO A/C>
|
|
| Date of change | From 29 February to 6 March 2024. | |
|
||
| No. of securities held prior to change |
Irwin Biotech Nominees Pty Ltd <BIO A/C> 870,494 Ordinary shares
Irwin Biotech Nominees Pty Ltd 20,000 Ordinary shares 865,827 Ordinary shares (represented by 28,861 American Depositary Receipts)
RIP Opportunities Pty Ltd 75,000 Ordinary shares (represented by 2,500 American Depositary Receipts)
RIP Opportunities Pty Ltd <PIR Super Fund A/C> 1,250,000 Ordinary shares |
| + See chapter 19 for defined terms. | |
| Appendix 3Y Page |
01/01/2011 |
Appendix 3Y
Change of Director’s Interest Notice
| Class | Ordinary shares | |
| Number acquired | 617,209 | |
| Number disposed | Nil | |
|
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation |
$80,315.18, an average of approximately 13 cents per ordinary share.
|
|
| No. of securities held after change |
Irwin Biotech Nominees Pty Ltd <BIO A/C> 1,487,703 Ordinary shares
Irwin Biotech Nominees Pty Ltd 20,000 Ordinary shares 865,827 Ordinary shares (represented by 28,861 American Depositary Receipts)
RIP Opportunities Pty Ltd 75,000 Ordinary shares (represented by 2,500 American Depositary Receipts)
RIP Opportunities Pty Ltd <PIR Super Fund A/C> 1,250,000 Ordinary shares |
|
|
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back |
On Market Trades
|
| + See chapter 19 for defined terms. | |
| Appendix 3Y Page |
01/01/2011 |
Appendix 3Y
Change of Director’s Interest Notice
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A | |
|
Nature of interest |
N/A | |
|
Name of registered holder (if issued securities) |
N/A | |
| Date of change | N/A | |
|
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed |
N/A | |
| Interest acquired | N/A | |
| Interest disposed | N/A | |
|
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation |
N/A | |
| Interest after change | N/A |
Part 3 – +Closed period
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No | |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A | |
| If prior written clearance was provided, on what date was this provided? | N/A |
| + See chapter 19 for defined terms. | |
| Appendix 3Y Page |
01/01/2011 |